title: The use of blood conservation methods in addition to erythropoietin allows myeloablative allogeneic stem cell transplantation without the use of blood products.
authors.forename: S
authors.initials: S
authors.lastname: Ciurea
authors.forename: R
authors.initials: R
authors.lastname: Beri
authors.forename: L
authors.initials: L
authors.lastname: Dobogai
authors.forename: S
authors.initials: S
authors.lastname: Chunduri
authors.forename: N
authors.initials: N
authors.lastname: Mahmud
authors.forename: D
authors.initials: D
authors.lastname: Rondelli
authors.forename: D
authors.initials: D
authors.lastname: Peace
mesh_terms: D000328:Adult; D001793:Blood Preservation / Q000379:methods; D001804:Blood Transfusion, Autologous / Q000523:psychology; D004921:Erythropoietin / Q000494:pharmacology*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D033221:Jehovah's Witnesses / Q000523:psychology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D011994:Recombinant Proteins; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin